نمایش پرونده ساده آیتم

dc.contributor.authorAlipour, S
dc.contributor.authorNouri, M
dc.contributor.authorKhabbazi, A
dc.contributor.authorSamadi, N
dc.contributor.authorBabaloo, Z
dc.contributor.authorAbolhasani, S
dc.contributor.authorFarhadi, J
dc.contributor.authorRoshanravan, N
dc.contributor.authorJadideslam, G
dc.contributor.authorSakhinia, E
dc.date.accessioned2018-08-26T08:57:15Z
dc.date.available2018-08-26T08:57:15Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54550
dc.description.abstractInterleukin-10 (IL-10), produced generally by monocyte, T helper type 2 (Th2), and regulatory T cells (Treg), plays a central role in controlling inflammatory responses and regulating the immune response of the IL-10 mRNA expression. It is significantly down-regulated in many autoimmune diseases such as Behçet's disease; this is mostly associated with more aggressive complications. Nevertheless, the essential molecular process for its low expression has not been completely realized. The aim of this project was attempted to estimate the gene expression, promoter methylation, and protein levels to IL-10's down-regulated expression. In this study, blood samples from 51 (4 missed) patients and 63 (2 missed) healthy controls were taken, with the mononuclear cells isolated by the Ficoll Protocol. DNA and RNA were then subsequently extracted. Promoter methylation levels were evaluated by MeDIP-qPCR. Following this, the extracted RNA was converted to cDNA using the RT-PCR method, with the expression of IL-10 later evaluated by Real-time PCR. And then, serum levels of IL-10 were measured using ELISA method. As we expected, the expression level of the IL-10 gene was seen to significantly decline in the patient group in comparison to the control. Also, the rate of promoter methylation was significantly higher in the IL-10 mRNA low expression group (patient group) compared to its high expression group (healthy group) (P < 0.001). We revealed that hypermethylation of promoter region was the principal defect for the IL-10 mRNA low expression in patients with Behçet's disease. é 2018 Wiley Periodicals, Inc.
dc.language.isoEnglish
dc.relation.ispartofJournal of Cellular Biochemistry
dc.subjectbeta actin
dc.subjectDNA
dc.subjectDNA fragment
dc.subjectHLA B27 antigen
dc.subjectHLA B51 antigen
dc.subjectinterleukin 10
dc.subjectmessenger RNA
dc.subjectRNA
dc.subjectadolescent
dc.subjectadult
dc.subjectArticle
dc.subjectBehcet disease
dc.subjectblood analysis
dc.subjectblood sampling
dc.subjectcell isolation
dc.subjectclinical evaluation
dc.subjectclinical protocol
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectDNA extraction
dc.subjectDNA methylation
dc.subjectdown regulation
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectgene expression
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectperipheral blood mononuclear cell
dc.subjectpriority journal
dc.subjectpromoter region
dc.subjectprotein expression
dc.subjectreal time polymerase chain reaction
dc.subjectreverse transcription polymerase chain reaction
dc.subjectRNA extraction
dc.titleHypermethylation of IL-10 gene is responsible for its low mRNA expression in Behçet's disease
dc.typeArticle
dc.citation.volume119
dc.citation.issue8
dc.citation.spage6614
dc.citation.epage6622
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1002/jcb.26809


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم